Первый опыт лучевого лечения плоскоклеточного рака орофарингеальной зоны с радиомодификацией цетуксимабом и цисплатином

1. Клинические рекомендации ESMO по диагностике, лечению, наблюдению при плоскоклеточных раках головы и шеи. ESMO 2007 г.
2. Матякин Е.Г., Алферов В.С. Химиотерапия опухолей головы и шеи. Материалы Второй ежегодной Российской онкологической конференции «Современные тенденции развития лекарственной терапии опухолей» 8–10 декабря 1998 г., Москва.
3. Adelstein DJ, Li Y, Adams GL et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21 (1): 2–8.
4. Adelstein DJ, Saxton JP, Rybicki LA et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 2006; 24 (7): 1023–5.
5. Bonner JA, Giralt J, Harari P et al. Cetuximab prolongs survival in patients with locally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (14S): Abstr 5507.
6. Bonner JA, Harari PM et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. New Engl J Med 2006; 354: 567–78.
7. Bourhis J, Armand C, Pignon JP. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (14S): Abstr 5505 (and virtual meeting presentation http://www.asco.org).
8. Сalais G, Аlfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Nat Cancer Inst 1999; p. 2081–6.
9. Calais G, Pointreau Y, Alfonsi M et al. Randomized phase III trial comparing induction chemotherapy using cisplatinum, fluorouracil with or without docetaxel for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01. Program and abstracts of the American Society of Clinical Oncology 2006 Annual Meeting; June 2–6, 2006. Atlanta, Georgia. Abstr 5506.
10. Chung CH, Ely K, Carter J. et al. High gene copy number of epidermal growth factor receptor by fluorescence in situ hybridization is frequent in head and neck squamous cell carcinomas and associates with worse recurrence-free survival. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings. Part I. 2006; 24 (18; Suppl.): 5502.
11. Dimery YW, Hong WK. Overview of Combined Modality Therapies for Head and Neck cancer. National Cancer Institute 1993; 85 (2): 95–111.
12. Domenge C, Hill C, Lefebvre J et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br J Cancer 2000; 83: 1594–8.
13. Feng FY, Lopez CA, Normolle DP et al. Effect of epidermal growth factor receptor inhibitor class in the treatment of Head and neck cancer with concurrent radiochemotherapy in vivo. Clin Cancer Res 2007; 13 (8): 2512–8.
14. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001; 92: 1331–46.
15. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitive immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78: 1284–92.
16. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001; 49: 427–33.
17. Harari PM, Ritter MA, Petereit DG, Mehta MP. Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. Curr Probl Cancer 2003; 28: 7–40.
18. Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23 (24): 5578–87.
19. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis and radiosensivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935–40.
20. List M, Siston A, Haraf D et al. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol 1999; 17: 1020–8.
21. Milas L, Mason K, Hunter N et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6: 701–8.
22. Pignon JP, Bourhis J, Domenge C, Design? L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355 (9208): 949–55.
23. Posner M, Hershock D, Le Lann L et al. A phase III multicenter trial of docetaxel cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Program and abstracts of the American Society of Clinical Oncology 2006 Annual Meeting; June 2–6, 2006. Atlanta, Georgia. Special Scientific Session.
24. Remenar E, Van Herpen C, Germa Lluch J et al. A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil versus neoadjuvant PF in patients with locally advanced, unresectable squamous cell carcinoma of the head and neck. Final analysis of EORTC 24971. Program and abstracts of the American Society of Clinical Oncology 2006 Annual Meeting; June 2–6, 2006. Atlanta, Georgia. Abstr 5516.
25. Salama et al. Chemoradiotherapy for Locally Advanced Head and Neck Cancer J Clin Oncol 2007; 25: 4118–26.
26. Trigo J, Hitt R, Koralewski P et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (14S): Abstr 5502 (and virtual meeting presentation http://www.asco.org).
27. Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25 (16): 2171–7.
28. Vokes EE, Weichselbaum RR, Lippman S, Hong WK. Head and neck cancer. N Engl J Med 1993; 328: 184–94.
30. Wanebo HJ, Ghebremichael M et al. Phase II evaluation of cetuximab (c225), combined with induction paclitaxel and carboplatin followed by c225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck.

А.В.Бойко, Л.В.Болотина, А.В.Черниченко, А.Р.Геворков, А.К.Смирнов

МНИОИ им. П.А.Герцена, Москва